Advertisement
Advertisement
ANIP
ANI Pharmaceuticals, Inc.
73.28
USDSponsored
-0.64
-0.87%
Mar 24, 15:59 UTC -4
Closed
After-Market
73.28
0.00
0.00%
ANIP Earnings Reports
Positive Surprise Ratio
ANIP beat 27 of 41 last estimates.
66%
Next Report
Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
$214.16M
/$1.50
Implied change from Q4 25 (Revenue/ EPS)
-13.32%
/-35.62%
Implied change from Q1 25 (Revenue/ EPS)
+8.64%
/-11.76%
ANI Pharmaceuticals, Inc. earnings per share and revenue
On Feb 27, 2026, ANIP reported earnings of 2.33 USD per share (EPS) for Q4 25, beating the estimate of 2.03 USD, resulting in a 14.48% surprise. Revenue reached 247.06 million, compared to an expected 236.16 million, with a 4.61% difference. The market reacted with a -4.21% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of 1.50 USD, with revenue projected to reach 214.16 million USD, implying an decrease of -35.62% EPS, and decrease of -13.32% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.37
Surprise
-706.10%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
$0.09
Actual
$0.05
Surprise
-45.53%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Cellectis S.A. - ADR
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.26
Surprise
+1.78%
Eledon Pharmaceuticals, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.20
Actual
-$0.10
Surprise
+51.78%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Milestone Pharmaceuticals Inc. Common Shares
Report Date
Mar 20, 2026 For Q4 25
Estimate
-$0.16
Actual
-$0.16
Surprise
+1.96%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
Pelthos Therapeutics Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$4.21
Actual
-$2.83
Surprise
+32.82%
Abivax SA - ADR
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.52
Actual
-$1.02
Surprise
+32.82%
FAQ
What were ANI Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, ANI Pharmaceuticals, Inc. reported EPS of $2.33, beating estimates by 14.48%, and revenue of $247.06M, 4.61% above expectations.
How did the market react to ANI Pharmaceuticals, Inc.'s Q4 2025 earnings?
The stock price moved down -4.21%, changed from $77.15 before the earnings release to $73.90 the day after.
When is ANI Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for May 07, 2026.
What are the forecasts for ANI Pharmaceuticals, Inc.'s next earnings report?
Based on 7
analysts, ANI Pharmaceuticals, Inc. is expected to report EPS of $1.50 and revenue of $214.16M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement